L.J. Altfest & Co’s Viking Therapeutics VKTX Stock Holding History

L.J. Altfest & Co’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,696	Closed	-$234K	–	370
2024 Q3	$234K	Buy	+3,696	New	+$217K	0.03%	303

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

L.J. Altfest & Co's VKTX Position: Q4 2024 in Review

L.J. Altfest & Co sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 3,696 shares — an estimated $234K sold.

L.J. Altfest & Co first reported a position in VKTX in Q3 2024 and held it in 1 quarter. The position peaked at $234K in Q3 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

L.J. Altfest & Co reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
L.J. Altfest & Co sold 3,696 Viking Therapeutics shares in Q4 2024, an estimated $234K.
L.J. Altfest & Co first reported a position in Viking Therapeutics in Q3 2024 and held it in 1 quarter.
L.J. Altfest & Co's Viking Therapeutics position peaked at $234K in Q3 2024.
408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on L.J. Altfest & Co's 13F filing for Q4 2024, filed 7 Feb 2025.